ArticleFrontiers in nutrition2025
Curcumin-piperine nanoparticles mitigate cuprizone-induced cognitive impairment via antioxidant and anti-inflammatory mechanisms.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Curcumin and piperine in neurodegenerative disorders: a systematic review of preclinical neuroprotective evidence.Frontiers in nutrition · 2026Pooled it
- Myrrh Oil-Based Nanoemulsion Loaded with Curcumin and Insulin: Development, Characterization, and Evaluation of Enhanced Antibacterial and Diabetic Wound-Healing Activity.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neuroinflammation is a key contributor to many neurodegenerative diseases. Cuprizone, a copper-chelating agent, is widely used in research to induce neurotoxicity and demyelination, mimicking the pathology of multiple sclerosis. This study investigates the protective and therapeutic effects of curcumin and piperine nanoformulations prepared in Methods: Seventy-five Swiss albino mice were divided into five groups: control, cuprizone-treated, blank formulation-treated, curcumin-treated, and curcumin with piperine-treated groups. Behavioral assessments, along with biochemical and histological analyses of the hippocampus, were conducted to evaluate learning and memory, antioxidant enzyme activity, neuroinflammatory markers, and cellular integrity. Results: Cuprizone exposure significantly impaired cognitive function and induced oxidative stress, as evidenced by decreased levels of key antioxidant enzymes like catalase, superoxide dismutase, glutathione and glutathione peroxidases. Additionally, increased levels of neuroinflammatory markers such as GFAP, MCP-1, MIP-1, and CCL-5 were observed. Treatment with curcumin and piperine nanoformulations mitigated these effects by restoring antioxidant defenses and modulating inflammatory responses. The curcumin-piperine combination exhibited superior neuroprotection compared to curcumin alone, enhancing memory performance and reducing neuroinflammation more effectively. The results highlight the potential of curcumin and piperine nanoformulations in alleviating neurotoxicity and cognitive impairments associated with neurodegenerative disorders. Conclusion: These findings suggest that curcumin-based nanoformulations could serve as promising therapeutic agents for treating neuroinflammatory diseases, warranting further studies to explore their precise mechanisms and optimize their clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.